Resources

The FDA approved the 90-day version of the implantable CGM Sensor.

For those who use insulin, accuracy is one of the most important things to consider when using a CGM.

“Simple,” “Accurate,” and “Effective” were the words ADA presenters used to describe Dexcom G6, a new continuous glucose monitor (CGM) system.

A dual-hormone, artificial pancreas delivering rapid insulin and the drug pramlintide improved glucose management and reduced glucose variability in adults with type 1 compared to an insulin-only, first-generation artificial pancreas.

Do you recommend a CGM for all your patients who are not achieving their target blood glucose and who are on insulin? Follow the link to respond.

Mr. Huang manages his diabetes with his lifestyle modifications, metformin, and linagliptin, and returns every 6 months for follow-up visits. Three years after initiating this treatment plan, he returns to your clinic for his 6-month check-up. When asked how his diabetes management is going at home, he shares that recently he has been “unable to really get out and get as much exercise as he knows he should due to his creaky, old knees acting up.” His current office A1C is 8.8%. You discuss with him what the next management steps may be to achieve his individualized glycemic goal. What would your next medical management step be? A. Add a rapid-acting insulin analogue B. Add a long-acting insulin analogue C. Add a GLP-1 agonist D. Add a sulfonylurea Follow the link for the answer.

What I love about going to conferences is the realization that what I’m doing in my practice is in line with what others I respect are doing. That is meaningful, and I always learn a new pearl. If that’s all I gain from these conferences, it’s okay, but it’s usually more than that. I have just returned from the 2018 ADA Conference, where there was so much about new technology, particularly continuous glucose monitoring.

Scott Kahan, MD, MPH is the Director of the National Center for Weight and Wellness. He is a physician trained in both clinical medicine and public health. He serves on the faculties of the Johns Hopkins Bloomberg School of Public Health, the George Washington University School of Medicine, and the George Washington University School of Public Health and Health Services.

In this week's Homerun Slides, the benefits of health and disease management programs, which can integrate evidence-based best practices into patient care.

The natural history of T2DM has been well described in multiple populations and is reviewed in references [1] and [3]. Individuals destined to develop T2DM inherit a set of genes from their parents that make their tissues resistant to insulin and the insulin resistance is aggravated by weight gain and physical inactivity. Hepatic insulin resistance is manifested by an overproduction of glucose during the basal state despite the presence of fasting hyperinsulinemia [38] and an impaired suppression of hepatic glucose production (HGP)